1. Home
  2. HRMY vs TY Comparison

HRMY vs TY Comparison

Compare HRMY & TY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRMY
  • TY
  • Stock Information
  • Founded
  • HRMY 2017
  • TY 1929
  • Country
  • HRMY United States
  • TY United States
  • Employees
  • HRMY N/A
  • TY N/A
  • Industry
  • HRMY Biotechnology: Pharmaceutical Preparations
  • TY Finance Companies
  • Sector
  • HRMY Health Care
  • TY Finance
  • Exchange
  • HRMY Nasdaq
  • TY Nasdaq
  • Market Cap
  • HRMY 1.8B
  • TY 1.6B
  • IPO Year
  • HRMY 2020
  • TY N/A
  • Fundamental
  • Price
  • HRMY $34.00
  • TY $32.00
  • Analyst Decision
  • HRMY Strong Buy
  • TY
  • Analyst Count
  • HRMY 9
  • TY 0
  • Target Price
  • HRMY $54.44
  • TY N/A
  • AVG Volume (30 Days)
  • HRMY 642.5K
  • TY 43.0K
  • Earning Date
  • HRMY 08-05-2025
  • TY 01-01-0001
  • Dividend Yield
  • HRMY N/A
  • TY 3.36%
  • EPS Growth
  • HRMY 13.13
  • TY N/A
  • EPS
  • HRMY 2.62
  • TY 4.78
  • Revenue
  • HRMY $744,852,000.00
  • TY N/A
  • Revenue This Year
  • HRMY $20.10
  • TY N/A
  • Revenue Next Year
  • HRMY $18.01
  • TY N/A
  • P/E Ratio
  • HRMY $13.10
  • TY $6.38
  • Revenue Growth
  • HRMY 20.62
  • TY N/A
  • 52 Week Low
  • HRMY $26.47
  • TY $25.16
  • 52 Week High
  • HRMY $41.61
  • TY $30.73
  • Technical
  • Relative Strength Index (RSI)
  • HRMY 58.91
  • TY 64.37
  • Support Level
  • HRMY $31.70
  • TY $31.59
  • Resistance Level
  • HRMY $35.08
  • TY $32.14
  • Average True Range (ATR)
  • HRMY 0.95
  • TY 0.39
  • MACD
  • HRMY 0.27
  • TY 0.04
  • Stochastic Oscillator
  • HRMY 71.80
  • TY 91.25

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About TY Tri Continental Corporation

Tri-Continental Corp is a United States-based closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.

Share on Social Networks: